Efficacy of a web-based monitoring program for teenagers with IBD - - PowerPoint PPT Presentation

▶
efficacy of a web based monitoring program for teenagers
SMART_READER_LITE
LIVE PREVIEW

Efficacy of a web-based monitoring program for teenagers with IBD - - PowerPoint PPT Presentation

May 28, 2023 43 likes •264 views

Efficacy of a web-based monitoring program for teenagers with IBD Anke Heida , Anke Santema, Alie Dijkstra, Henk Groen, Patrick van Rheenen Disclosure This trial: Buhlmann Laboraties provided kits for measuring fecal Calprotectin For

slide-1
SLIDE 1

Efficacy of a web-based monitoring program for teenagers with IBD

Anke Heida, Anke Santema, Alie Dijkstra, Henk Groen, Patrick van Rheenen

slide-2
SLIDE 2

Disclosure

  • This trial: Buhlmann Laboraties provided kits for measuring

fecal Calprotectin

  • For other trials we received support from CisBio Bioassays

(producer fecal marker S100A12) and Buhlmann Laboratories (producer fecal marker Calprotectin).

slide-3
SLIDE 3

Telemedicine solutions are supposed to be the future Applicable? Cost-effective? Practical?

slide-4
SLIDE 4

IBD-live: teenagers at the wheel

slide-5
SLIDE 5

Inflammatory Bowel Disease

(Crohns disease and Ulcerative Colitis)

slide-6
SLIDE 6

Monitoring disease activity at pre-set timepoints

slide-7
SLIDE 7

Aim

Comparing the efficacy of a web-based monitoring system with usual care.

Heida A et al. Trials 2015

slide-8
SLIDE 8

Multicenter randomized controlled trial

IBD-live headquarter Academic hospital General hospital

slide-9
SLIDE 9

In- and exclusion criteria

  • Teenagers:10-19 years
  • IBD diagnosis > 6 months
  • Quiescent IBD > 3 months
  • Access to internet
  • Dutch language
  • Treatment with biologicals
  • Comorbidity requiring

frequent hospital visits

  • Ileostomy or ileoanal pouch
slide-10
SLIDE 10

Study endpoints

  • Efficacy (Time-to-relapse)
  • Cost-effectiveness (societal perspective)
  • Quality of life (IMPACT III questionnaire)

AH2

slide-11
SLIDE 11

Slide 10 AH2 Quality of life en patients' experience weglaten??

A Heida, 02/06/2016

slide-12
SLIDE 12

Studyflow

IBD-live

(n=90)

Usual care

(n=90)

9 6 6 3 3 9 5 1 2 7 8

R

12 12

slide-13
SLIDE 13

Flarometer

slide-14
SLIDE 14

Flarometer

PUCAI PCDAI Fecal Calprotectin

slide-15
SLIDE 15

Interim analysis

20 40 60 80 100 120 140 160 180 Number of patients included

Jun ‘13 Jan ‘16

slide-16
SLIDE 16

No difference in baseline characteristics

IBD-live (N=53) Usual care (N=67) Age at baseline (median, IQR) 15.3 (12.9-16.7) 15.6 (13.8-17.0) Male N(%) 30 (45%) 31 (58%) Crohns disease N(%) 23 (43%) 34 (51%) Ulcerative Colitis N(%) 30 (57%) 33 (49%)

slide-17
SLIDE 17

No difference in time-to-relapse

  • Kaplan Meijer curve

IBD-live Usual care Months % of patients without relapse

slide-18
SLIDE 18

IBD-live: less outpatient visits

IBD-live (N=53) Usual care (n=67) No of scheduled visits 130 225 No of unscheduled visits 28 21 No of patients with unscheduled visit 14 (26.4%) 14 (20.9%) No of hospital admissions 1 3

slide-19
SLIDE 19

IBD-live vs usual care

  • No difference in time-to-relapse
  • Reduction of number of hospital visits
slide-20
SLIDE 20

Limitations and perspectives

  • Interim analysis
  • Cost-effectiveness analysis: work in progress
slide-21
SLIDE 21

Acknowledgements

  • IBD-live study team: Patrick van Rheenen, Alie Dijkstra, Anke

Santema, Anneke Muller Kobold, Henk Groen, Henkjan Verkade, Angelika Kindermann

  • Participating centers:
  • Funded by
  • Supported by
  • Images made by Studio Ex or downloaded from freepik.com
slide-22
SLIDE 22

Thank you for your attention